Amneal Pharmaceuticals (AMRX) Gross Profit (2017 - 2026)

Amneal Pharmaceuticals' Gross Profit history runs 10 years deep, the most recent figure standing at $320.1 million for Q1 2026.

• On a quarterly basis, Gross Profit rose 25.1% year-over-year to $320.1 million in Q1 2026; TTM through Mar 2026 was $1.2 billion, a 13.41% increase from a year earlier, with the FY2025 full-year figure at $1.1 billion, up 9.1% from the prior year.
• Gross Profit grew to $320.1 million in Q1 2026 per AMRX's latest filing, from $297.2 million in the prior quarter.
• Across five years, Gross Profit topped out at $320.1 million in Q1 2026 and bottomed at $174.6 million in Q1 2022.
• The 5-year median for Gross Profit is $238.1 million (2024), against an average of $238.8 million.
• Across the five-year window, Gross Profit retreated 11.87% in 2023 and surged 38.48% in 2024, its largest moves.
• Year by year, Gross Profit stood at $215.4 million in 2022, then retreated by 11.87% to $189.8 million in 2023, then soared by 38.48% to $262.9 million in 2024, then increased by 13.05% to $297.2 million in 2025, then grew by 7.71% to $320.1 million in 2026.
• Per Business Quant, the three latest AMRX Gross Profit figures stand at $320.1 million (Q1 2026), $297.2 million (Q4 2025), and $274.0 million (Q3 2025).